New Jersey Assembly Bill AR90

New Jersey 2022-2023 Regular Session

• Introduced: 2/28/22
• Refer: 2/28/22

Caption

Urges FDA to make naloxone available over the counter.

Impact

If enacted, AR90 would pave the way for naloxone to be more readily available to individuals at risk of opioid overdose, their families, and emergency responders. This initiative aligns with previous legislative efforts in New Jersey, such as the 'Overdose Prevention Act,' which protects individuals seeking medical help in overdose incidents from prosecution. The resolution indicates a significant step toward enhancing public health measures aimed at preventing overdose deaths, particularly as the opioid crisis continues to escalate.

Summary

Assembly Resolution No. 90 (AR90) was introduced in the New Jersey Legislature to urge the Food and Drug Administration (FDA) to make naloxone available over the counter without a prescription. This resolution highlights the increasing rates of drug-related deaths in the state, particularly due to heroin and opioid abuse among young adults. By advocating for the accessibility of naloxone, the resolution aims to provide immediate tools to combat overdose situations, thereby saving lives and addressing the opioid crisis in New Jersey.

Contention

Despite the resolution's aim to improve public health, there may be contention surrounding its implications for regulation and accessibility. Some opponents of such measures argue that increased access to naloxone could inadvertently lead to greater opioid usage or lessen the urgency for treatment. However, research cited in the resolution asserts that making naloxone available does not encourage this behavior, which will likely be a focal point in discussions surrounding the resolution’s perceived benefits and drawbacks.